MicroRNAs Profiling in Murine Models of Acute and Chronic Asthma: A Relationship with mRNAs Targets

Nancy Garbacki1, Emmanuel Di Valentín2, Ván Anh Huỳnh-Thu3, Pierre Geurts3, Alexandre Irrthum3, Céline Crahay4, Thierry Arnauld5, Christophe Deroanne1, Jacques Piette2, Didier Cataldo4, Alain Colige1*

1 GIGA-Research, Laboratory of Connective Tissues Biology, University of Liège, Liège, Belgium, 2 GIGA-Research, Laboratory of Intestinal Microbiome, University of Liège, Liège, Belgium, 3 GIGA-Research, Systems and modeling, University of Liège, Liège, Belgium, 4 GIGA-Research, Laboratory of Biology of Tumours and Development, University of Liège, Liège, Belgium, 5 Laboratory of Biochemistry and Cell Biology, University of Namur, Namur, Belgium

Abstract

Background: miRNAs are now recognized as key regulator elements in gene expression. Although they have been associated with a number of human diseases, their implication in acute and chronic asthma and their association with lung remodelling have never been thoroughly investigated.

Methodology/Principal Findings: In order to establish a miRNAs expression profile in lung tissue, mice were sensitized and challenged with ovalbumin mimicking acute, intermediate and chronic human asthma. Levels of lung miRNAs were profiled by microarray and in silico analyses were performed to identify potential mRNA targets and to point out signalling pathways and biological processes regulated by miRNA-dependent mechanisms. Fifty-eight, 66 and 75 miRNAs were found to be significantly modulated at short-, intermediate- and long-term challenge, respectively. Inverse correlation with the expression of potential miRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. A functional validation assay was performed by cotransfecting in human lung fibroblasts (WI26) synthetic miRNAs and engineered expression constructs containing the coding sequence of luciferase upstream of the 3’UTR of various potential miRNA targets. The bioinformatics analysis identified miRNA-linked regulation of several signalling pathways, as matrix metalloproteinases, inflammatory response and TGF-β signalling, and biological processes, including apoptosis and inflammation.

Conclusions/Significance: This study highlights that specific miRNAs are likely to be involved in asthma disease and could represent a valuable resource both for biological makers identification and for unveiling mechanisms underlying the pathogenesis of asthma.

Introduction

Asthma is a complex chronic inflammatory disease characterized by eosinophilic airway inflammation, reversible airway obstruction and hyper-responsiveness. Moreover, asthma patients display a faster rate of lung dysfunction than normal individuals related to a progressive remodelling of airway walls [1,2]. Major features of this remodelling process consist of epithelial damages, smooth muscle cell hyperplasia, glandular hyperplasia and airway wall fibrosis including a thin collagen layer deposition in the lamina reticularis of airway epithelium [2,3]. To date, marketed asthma treatments are not sufficient to allow a satisfactory level of control in every patient and are not effective towards airways remodelling processes. For these reasons, identification of new therapeutic targets and new biomarkers relevant for diagnosis and prognosis evaluation are eagerly needed.

The evolution of the disease from acute inflammation to the fibrotic process is driven by soluble factors, such as cytokines and chemokines, and by cell-cell and cell-matrix interactions. An abundant literature [4–10] shows that these regulatory signals affect the level of transcription of several genes in leukocytes and in specific lung cells. These transcriptomic studies led to the identification of several potential new therapeutic targets but largely failed to provide information about regulations operated at a post-transcriptional level. MicroRNA-driven RNA interference is a newly recognized and evolutionary conserved regulatory mechanism. MiRNAs lead to the degradation and/or repression of translation of specific mRNAs depending on the type of base-pairing between the miRNA and its mRNA target [11]. In mammals miRNA-dependent regulation mostly affects the translation process although moderate and variable levels of degradation of
the target are also often associated. Most interestingly, this opens the possibility of inferring the existence of potent miRNA-driven translational regulation from powerful and validated whole genome transcriptomic studies. Taking into account that each mammal genome contains several hundreds of miRNA [12], that the complementarities between a miRNA and its target sequence are usually not perfect, that a single miRNA may regulate the translation/degredation of many mRNAs and that a single miRNA can be affected by several different miRNAs, one can consider that this type of investigation requires the use of powerful bioinformatics tools able to analyse such complex pattern of interactions. Although miRNA expression modulations have already been associated with several human diseases [13–30], only few studies have explored the role of miRNAs in non-tumoral lung diseases [31–38] and very little is known about miRNAs expression profiles in the lung during the course of asthma and asthma-induced airway remodelling.

In the present study, microarray analysis has been used to determine miRNAs expression profiles in a mouse model of asthma designed to investigate the development of both acute and chronic responses to allergen. Moreover, in silico analysis and comparison with the expression profile of miRNAs in the same pathological state identified several genes and pathways that are both involved in asthma and post-transcriptionally regulated by miRNA-dependent processes. The best candidates were validated by functional assays in cell culture.

**Results and Discussion**

**Assessment of airway inflammation, sensitization and hyperresponsiveness in mouse model of asthma**

Mouse models of asthma are commonly considered as reliable tools to study pathological mechanisms of the disease since these animals, if adequately sensitized and exposed to allergens, develop measurable airway hyperresponsiveness, airway inflammation, and finally airway remodelling if the exposure to allergens persists [39–41].

The mouse model of asthma used in this study has previously been characterized [4]. In comparison to control mice, animals exposed to allergen showed an enhanced airway resistance after increasing doses of metacholine as compared with the corresponding PBS-exposed groups (Figure 1A). Percentages of goblet cells in the bronchial epithelium (Figure 1B) and subepithelial collagen deposition (Figure 1C) did increase over time in allergen-exposed mice. Eosinophil infiltration measured in bronchial walls was significantly increased in each allergen-exposed group as compared to controls while the eosinophils density in the bronchial walls decreased over time (Figure 1D). Exposure to aerosolized OVA induced a slight increase in differential cell numbers present in the BAL fluids when compared to their PBS-exposed counterparts (Table 1) which was expected from previous studies [40,42] and largely resulted from eosinophilic representation.

Reproducibility of our mouse model of asthma induction was further assessed by measuring in each individual mouse of the current study. The relative abundance of 8 transcripts known from a previous study [4] to be regulated at the 3 time-points of allergen exposure (ST, IT and LT). The new data set is fully in agreement with previous quantifications, except for Cdc2a at ST and LT (Figure S1). All together these functional, cellular and transcriptomic evaluations demonstrate the reproducibility of our models of asthma from one experiment to another. These data allow us to use the transcriptomic data from our previous study [4] to relate mRNA targets with the miRNAs identified in this study. However, the animal model of asthma used here can also bear per se some limitations. For instance, allergen used in animals (ovalbumin) is not a causative agent of human asthma in physiological conditions. The animals are also anatomically different from human regarding bronchial architecture since number of bronchial divisions is lower in mice. Nevertheless, this model with its intrinsic limitations allowed the investigators to reproduce all key features of asthmatic airways as found in humans with an allergen-induced airway inflammation and hyperresponsiveness as well as an allergen-induced airway remodelling (figure 1A–D).

**MiRNA expression changed in lungs during allergen exposure**

Lung total RNA was obtained from groups of mice exposed to allergen (OVA) or control (PBS) for 1 (ST), 5 (IT) and 10 (LT) weeks. Microarray analysis indicated that 58, 66 and 75 mature miRNAs out of 566 were significantly (p-value <0.01) modulated at ST, IT and LT, respectively (Table S1). For many of them, the fold induction or repression in the OVA-treated mice was higher than 1.5 (20 at ST, 26 at IT and 67 at LT) (Table 2). Some miRNAs underwent a significant modulation (≥1.5-fold, p-value <0.01) at two time-points but only one, mmu-miR-146b, was consistently upregulated at the three investigated time-points (Table 3).

**Modulated miRNAs after short term (ST) and intermediate term (IT) exposure to allergen.** Mmu-miR-690 was downregulated at ST and IT but was no longer modulated at LT. In the literature, this miRNA was only reported to be significantly downregulated in pancreatic β cells after treatment with high glucose [43]. The second miRNA significantly regulated, mmu-miR-223, was previously shown to play a significant role in pulmonary function alteration by exposition to cigarette smoke [31] or to LPS [33]. It is also known to be involved in hematopoietic development [44–47], to be expressed by PBMC [48] and neutrophils [33] and to be implicated in malignancies such as ovarian cancer [49], hepatocellular carcinoma [50] and bladder cancer [51].

**Modulated miRNAs after short term (ST) and long term (LT) exposure to allergen.** Three miRNAs, mmu-miR-672, -574-5p and -483 were downregulated at ST and upregulated at LT. To our knowledge, only miR-483 has been previously associated to a specific disease or a physiological state and was found to be significantly correlated with cardiac hypertrophy [52].

**Modulated miRNAs after intermediate term (IT) and long term (LT) exposure to allergen.** Mmu-miR-423-5p, -455, -466f-3p, -466g, -467a* and -467b* were consistently upregulated at IT and LT. Among these miRNAs, miR-455 has been reported to be implicated in brown adipocyte differentiation [53], while the functions or targets of the others are not determined yet. These miRNAs could become interesting markers of late phases of asthma development as they are significantly upregulated. By contrast to these six miRNAs, mmu-miR-29c is downregulated at these two time-points. Mir-29 has been reported to be involved in various human cancers [54–57] and in tumour suppression by targeting the T-cell leukemia/lymphoma 1 (Tcl1) oncogene miRNA [54], by reverting DNA methylation by targeting DNA methyltransferases 3A (Dnmt3a) and 3B (Dnmt3b) mRNA [58] and by regulating p53 pathway through Cdc2 and p53x [59]. Moreover, its targets miRNAs encoding extracellular matrix proteins have been associated with cell migration and metastasis such as Col3a1, Col4a1, Col5a1, Lam1 and Col10a1 [60]. Mir-29 regulates also muscle cell differentiation probably, in part, under a feed-back control of NF-kB YY1 pathway [61].

**Modulated miRNAs after short term (ST), intermediate term (IT) and long term (LT) exposure to allergen.** Mmu-miR-146b was the only miRNA consistently upregulated during the entire time-course of the experiment. Mir-146b is expressed by leukocytes and its function is clearly associated with inflammation and innate immunity [33,62]. Taganov et al. [63]
showed that miR-146 regulatory circuit fine-tunes TLR and cytokine signalling, rather than totally abrogating the signal, in response to microbial components and proinflammatory cytokines. Moreover, this miRNA acts as a negative regulator of NF-κB activity in a human breast cancer cell line [64].

**Figure 1. Assessment of airway inflammation, sensitization and hyperresponsiveness.** Assessment of airway responsiveness to metacholine (Panel A), of glandular hyperplasia as percentage of goblet cells per total epithelial cells (Panel B), of peribronchial collagen deposition (Panel C) and of eosinophils accumulation (Panel D) in randomly selected bronchi in PBS and OVA-treated groups of mice at short-term (ST), intermediate-term (IT) and long-term (LT) sensitization and exposure protocols. Mean scores were measured as described in [4]. Results are expressed as means ± SE and the comparison between groups was performed using Mann-Whitney U test (* p-value <0.05; ** p-value <0.005; *** p-value <0.001; N.S.: not significant).

doi:10.1371/journal.pone.0016509.g001

**Table 1. Differential cell counts in BAL fluids.**

|                      | ST  | IT   | LT   |
|----------------------|-----|------|------|
|                      | PBS | OVA  | PBS  | OVA  |
| Epithelial cells (×10⁴/ml) | 4.9±0.8 | 4.7±1.9 | 1.8±0.8 | 3.5±0.7 |
| Eosinophils (×10⁷/ml)     | 5.2±1.7 | 75.0±30.7 | 1.6±0.4 | 8.1±1.5 |
| Lymphocytes (×10⁴/ml)    | 0.2±0.1 | 0.5±0.1 | 0.1±0.0 | 0.2±0.1 |
| Macrophages (×10⁴/ml)    | 36.9±6.0 | 22.1±6.1 | 17.6±1.1 | 22.9±3.6 |
| Neutrophils (×10⁴/ml)    | 0.1±0.0 | 2.1±0.1 | 0.1±0.0 | 0.6±0.2 |

Cellular composition of BAL fluid and absolute cell counts performed 24 hours after the last allergen or PBS exposure. ST, IT, LT: short, intermediate and long-term treatments, respectively.

doi:10.1371/journal.pone.0016509.t001

**Microarray validation**

Before considering further the potential implication of the regulation affecting the expression of several miRNAs, microarrays data, that were obtained by hybridization of RNA pools, were validated by RT-qPCR quantification for each individual
Table 2. List of significantly modulated mature miRNAs (≥1.5-fold, p-value < 0.01) and their respective fold induction at each time-point.

| miRNA   | FI  | miRNA   | FI  |
|----------|-----|----------|-----|
| ST       |      |          |     |
| mmu-miR-712* | 5.24 | mmu-miR-187 | 0.66 |
| mmu-miR-122 | 5.08 | mmu-miR-497 | 0.49 |
| mmu-miR-181d | 2.51 | mmu-miR-690 | 0.49 |
| mmu-miR-106a | 2.28 | mmu-miR-1  | 0.46 |
| mmu-miR-223 | 1.99 | mmu-miR-483 | 0.39 |
| mmu-miR-146b | 1.91 | mmu-miR-574-5p | 0.37 |
| mmu-miR-181b | 1.91 | mmu-miR-203 | 0.35 |
| mmu-miR-689 | 1.90 | mmu-miR-672 | 0.35 |
| mmu-miR-20b  | 1.88 | mmu-miR-805 | 0.28 |
| mmu-miR-451 | 1.60 |          |     |
| mmu-miR-100 | 1.52 |          |     |
| IT       |      |          |     |
| mmu-miR-155 | 4.48 | mmu-miR-322 | 0.66 |
| mmu-miR-467b* | 2.97 | mmu-miR-429 | 0.66 |
| mmu-miR-467a* | 2.79 | mmu-miR-199a-3p | 0.63 |
| mmu-miR-466g | 2.64 | mmu-miR-152 | 0.63 |
| mmu-miR-466f-3p | 2.23 | mmu-miR-29c | 0.62 |
| mmu-miR-455 | 2.03 | mmu-miR-218 | 0.62 |
| mmu-miR-150 | 1.80 | mmu-miR-200a | 0.59 |
| mmu-miR-423-5p | 1.69 | mmu-miR-10a | 0.59 |
| mmu-miR-146b | 1.55 | mmu-miR-10b | 0.53 |
| mmu-miR-375 | 1.52 | mmu-miR-29b | 0.52 |
|          |     | mmu-miR-101a | 0.36 |
|          |     | mmu-miR-223 | 0.32 |
|          |     | mmu-miR-19b | 0.31 |
|          |     | mmu-miR-690 | 0.24 |
|          |     | mmu-miR-450a-5p | 0.19 |
|          |     | mmu-miR-126-5p | 0.14 |
| LT       |      |          |     |
| mmu-miR-705 | 119.30 | mmu-miR-200b | 0.61 |
| mmu-miR-188-5p | 117.39 | mmu-miR-92a | 0.60 |
| mmu-miR-483 | 115.80 | mmu-miR-30c | 0.59 |
| mmu-miR-669c | 115.25 | mmu-miR-27a | 0.53 |
| mmu-miR-568 | 96.03 | mmu-let-7e | 0.50 |
| mmu-miR-467b* | 48.35 | mmu-miR-21 | 0.47 |
| mmu-miR-691 | 42.50 | mmu-miR-25 | 0.46 |
| mmu-miR-671-5p | 39.54 | mmu-miR-30b | 0.44 |
| mmu-miR-467a* | 39.02 | mmu-miR-23b | 0.41 |
| mmu-miR-485* | 33.41 | mmu-miR-23a | 0.38 |
| mmu-miR-744 | 29.56 | mmu-miR-26b | 0.31 |
| mmu-miR-466f-3p | 22.69 | mmu-miR-98 | 0.20 |
| mmu-miR-685 | 19.58 | mmu-miR-15a | 0.19 |
| mmu-miR-709 | 18.98 | mmu-miR-29c | 0.11 |
| mmu-miR-467e* | 18.51 |          |     |
| mmu-miR-466c-5p | 17.07 |          |     |
| mmu-miR-466g | 16.19 |          |     |

ST, IT, LT: short, intermediate and long-term treatments, respectively; FI: fold induction.

Table 2. Cont.

| UREGULATION | mmiRNA   | FI  | DOWNREGULATION | mmiRNA   | FI  |
|-------------|----------|-----|----------------|----------|-----|
| mmu-miR-574-3p | 15.99 |
| mmu-miR-574-5p | 13.18 |
| mmu-miR-667 | 13.13 |
| mmu-miR-713 | 11.83 |
| mmu-let-7d* | 11.72 |
| mmu-miR-762 | 11.22 |
| mmu-miR-466d-3p | 9.95 |
| mmu-miR-466b-3-3p | 9.89 |
| mmu-miR-466f-5p | 9.50 |
| mmu-miR-297a* | 9.21 |
| mmu-miR-468 | 8.99 |
| mmu-miR-466a-3p | 8.48 |
| mmu-miR-197 | 8.06 |
| mmu-miR-455 | 7.51 |
| mmu-miR-877* | 6.41 |
| mmu-miR-297a | 6.38 |
| mmu-miR-15a* | 6.14 |
| mmu-miR-207 | 6.03 |
| mmu-miR-346 | 5.84 |
| mmu-miR-466h | 5.54 |
| mmu-miR-206 | 5.48 |
| mmu-miR-328 | 5.38 |
| mmu-miR-672 | 5.30 |
| mmu-miR-214 | 5.29 |
| mmu-miR-320 | 4.52 |
| mmu-miR-34c* | 4.26 |
| mmu-miR-423-5p | 4.04 |
| mmu-miR-674 | 3.84 |
| mmu-miR-151-3p | 3.18 |
| mmu-miR-143 | 2.86 |
| mmu-miR-146b | 2.69 |
| mmu-miR-720 | 2.69 |
| mmu-miR-146a | 2.09 |
| mmu-miR-99b | 2.03 |
| mmu-miR-125b-5p | 1.88 |
| mmu-miR-145 | 1.75 |
| mmu-miR-30d | 1.64 |
| mmu-miR-191 | 1.59 |

ST, IT, LT: short, intermediate and long-term treatments, respectively; FI: fold induction.

doi:10.1371/journal.pone.0016509.t002
Table 3. miRNAs undergoing a significant modulation (≥ 1.5-fold, \(p\)-value < 0.01) determined by microarray analysis at, at least, 2 time-points.

| miRNA     | ST Induction | IT Induction | LT Induction |
|-----------|--------------|--------------|--------------|
| mmu-miR-690 | 0.49         | 0.24         | N.C.         |
| mmu-miR-223 | 1.99         | 0.32         | N.C.         |
| mmu-miR-672 | 0.35         | N.C.         | 5.31         |
| mmu-miR-574-5p | 0.37     | N.C.         | 13.18        |
| mmu-miR-483 | 0.39         | N.C.         | 116.16       |
| mmu-miR-29c | N.C.         | 0.62         | 0.11         |
| mmu-miR-423-5p | N.C.     | 1.69         | 4.03         |
| mmu-miR-455 | N.C.         | 2.03         | 7.52         |
| mmu-miR-466-3p | N.C.     | 2.23         | 22.63        |
| mmu-miR-466g | N.C.         | 2.64         | 16.22        |
| mmu-miR-467a | N.C.         | 2.79         | 39.12        |
| mmu-miR-467b | N.C.         | 2.97         | 48.50        |
| mmu-miR-146b | 1.91         | 1.55         | 2.69         |

ST, IT, LT: short, intermediate and long-term treatments, respectively; N.C.: no change between PBS and OVA.

doi:10.1371/journal.pone.0016509.t003

quantification. This pitfall was found to be related in part to the low level of some miRNAs and strongly related to the short size of mature miRNA preventing the design of highly specific primers. In order to overcome this technical problem, LNA-containing primers were designed to quantify these hard to amplify miRNAs (mmu-miR-146b, -29b and -29c). Quantitative RT-PCR was performed at the three time-points for 14 miRNAs, representing a total of 42 calculations of the OVA/PBS ratios based on individual mouse measurements. Among these data, 40 out of 42 (95%) gave results and trends similar to those obtained by microarray profiling, except for mmu-miR-29c at ST and LT (Figure 2), although the magnitude of the observed regulation was not always identical (mmu-miR-455 at LT and mmu-miR-450a at IT). Besides problems related to PCR amplification as experienced with mmu-miR-29c, another potential explanation for the differences observed between the two quantification procedures could be related to the relative abundance of precursor miRNA (pre-miRNA) that are characterized by the persistence of a stem-loop structure. Depending upon their sequence and stability, these stem-loops are indeed expected to affect differently the efficiencies of the RT-PCR amplifications and the hybridization with probes immobilized on microarrays. As a result, differences in microarrays and RT-PCR data for a specific miRNA may be related to modifications of the level of its pre-miRNA, thus to the regulation of its transcription.

All together, these data demonstrate that microarray analysis is reliable and allows to detect changes in the level of expression of a large panel of miRNAs, providing a unique opportunity to investigate the role of miRNA-based RNA interference during the course of asthma.

Several miRNAs were expected to participate in the regulation of biological processes during the course of asthma development

Knowing that miRNA can induce a significant degradation of its target and assuming also that evolution progressively selected inverse regulation of expression of miRNAs and their specific miRNAs, we determined (MicroCosm Target algorithm) for each miRNA its potential target(s) and the regulatory pathways that are expected to be regulated (Tables S2, S3 and S4). Among these results, we focused on predicted pairs of miRNAs and mRNAs that are inversely regulated at 2 time-points with a \(p\)-value < 0.05 (Table 4). The potential targets of mmu-miR-146b, the only miRNA being significantly upregulated throughout the experiment, were also identified (Table 5). Collectively, these 7 selected miRNAs are expected to participate in the regulation of several biological processes involved in asthma as illustrated in Figure 3.

Functional correlation between the expression of miRNAs and some of their potential targets. As shown in Tables 4 and 5, modulation of some miRNAs could be involved in the pathogenesis of asthma by regulating genes at acute and/or chronic stages of the disease. We selected 8 miRNAs (those described in Tables 4 and 5 and mmu-miR-29b) and, at least, 2 of their potential targets for functional testing in vitro (Figures 4 and 5).

In this assay, cells from lung origin were cotransfected with synthetic miRNA mimic or non-functional small RNA control and expression vectors containing the coding sequence of luciferase cloned upstream of either an irrelevant control 3'UTR or the 3'UTR of the respective potential mRNA target. In this experimental set up, the efficiency of the miRNA-dependent regulation was directly proportional to the decrease in luciferase activity used as a reporter.

For miR-146b, which was up-regulated at the 3 time-points, and for miR-29b and -29c, which are thought to be regulators of extracellular matrix remodelling and are downregulated at IT and LT, increasing concentrations were tested to evaluate the sensitivity and the specificity of the assays (Figure 4).

Despite their close sequence similarity, miR-29 members showed different inhibitory patterns. MiR-29b mimic reduced efficiently and dose-dependently the luciferase activity from constructs containing the 3'UTRs of mouse Mmp-15 and Mmp-24 while miR-29c had only a limited effect at high concentration on Mmp-24 3’UTR (Figure 4A, B). Since the sequence of miR-29b and -29c are identical in human and mouse, their efficiencies were also evaluated using the 3’UTRs of human Mmp-15 and Mmp-24. Similar regulations were observed using human and mouse 3’UTRs, which confirm both the specificity of the inhibitions and the relevance of our findings in the context of human asthma.

Among the 17 others miRNA-mRNA pairs that were evaluated (Figure 4E-H and Figure 5), significant inhibition was observed in 10 experimental conditions (miR-29c and Csk; miR-146b and Scube2b; miR-483 and Nola2 or Ube2c; miR-672 and Phb2; miR-223 and I6 or Lpin2 or Arid4b; miR-690 Fst or Cts). All together these validation analyses indicate that 64% (16/25) of the predicted regulations are effective while inhibitions were also observed in the 9 remaining cases but were too low to reach statistical significance. Although optimization of the experimental design (timing for sample collection, transfection conditions, target concentration…) would have probably led to the confirmation of other miRNA-mRNA regulatory pairs, these experiments were not further continued since the aim of these functional assays was only to validate the in silico predictions before addressing the potential roles of miRNAs during asthma.

Identification of biological processes regulated by miRNAs. Genes involved in transcriptional regulation are modulated at each time-point in our experimental model [4]. Four of selected miRNAs (Tables 4 and 5) displayed a clear correlation with this biological process at 2 or 3 time-points. The expression of mmu-miR-483 and -672 was downregulated at ST
as compared to the PBS-treated mice while the levels of mmu-miR-223 and -146b were increased. Their putative targets in this biological process embrace direct transcription initiator (TOP2A, topoisomerase II α), transcription factors (ZFP451, BTF3, KLF13 and TCFCP2L1), transcription coactivators (LPIN2) or corepressors (FOXP4, GMNN, PHB2) and proteins playing roles in functional organization of chromosome structure through chromatin remodeling (ARID4B).

We also observed that the mRNA potentially targeted by mmu-miR-223 (Arid4b, Lpin2, see Figure 5) and mmu-miR-146b (Zfp451, Klf13 and Tcfcp2l1) did undergo a downregulation at ST. This effect could be reinforced by the downregulation of mmu-miR-672, which potentially targets PHB2, a factor that restrains estrogen action and its activating pathway [65] and by repression of mmu-miR-483 that could be responsible for the observed upregulation of GMNN, an inhibitor of HOX-dependent transcriptional activity [66]. However, topoisomerase II α (Top2a) mRNA, which appears to be inversely correlated to mmu-miR-672 expression, was significantly upregulated at ST and downregulated at LT. An inversion in the pattern of transcription-related mRNA-miRNA modulations was shown at LT exposure to allergens. From these findings, it can be speculated that the potential role of miRNAs in the modulation of transcription mechanisms would mostly consist in a fine-tuning process rather than striking regulations.

Cell cycle. MiRNA targeting genes regulating cell cycle are clearly downregulated at ST, not affected at IT and upregulated at LT. GMNN, which negatively regulates cell cycle, and MKI67, which is an endogenous marker of proliferative cells, are putative targets of mmu-miR-483. The expression of CCNB1 (cyclin B1) that activates CDK1 driving G2/M-phase progression [67], of CDCA8 (borealin) that is required for the proper segregation of chromosomes during mitosis [68] and of NUSAP1 that is selectively expressed in proliferative cells and is a positive regulator of mitosis by acting on microtubules organization [69] were significantly inversely correlated to mmu-miR-574-5p

Figure 2. Validation of microarray data by real-time RT-qPCR. Comparison of miRNA level regulation as determined by microarray hybridization (several probes per target) performed on pooled total RNA and by RT-qPCR performed on total RNA of each individual mice. Results are expressed as means ± SD. The value “1” is arbitrarily given when no change is observed. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.g002

as compared to the PBS-treated mice while the levels of mmu-miR-223 and -146b were increased. Their putative targets in this biological process embrace direct transcription initiator (TOP2A, topoisomerase II α), transcription factors (ZFP451, BTF3, KLF13 and TCFCP2L1), transcription coactivators (LPIN2) or corepressors (FOXP4, GMNN, PHB2) and proteins playing roles in functional organization of chromosome structure through chromatin remodeling (ARID4B).

We also observed that the mRNA potentially targeted by mmu-miR-223 (Arid4b, Lpin2, see Figure 5) and mmu-miR-146b (Zfp451, Klf13 and Tcfcp2l1) did undergo a downregulation at ST. This effect could be reinforced by the downregulation of mmu-miR-672, which potentially targets PHB2, a factor that restrains estrogen action and its activating pathway [65] and by repression of mmu-miR-483 that could be responsible for the observed upregulation of GMNN, an inhibitor of HOX-dependent transcriptional activity [66]. However, topoisomerase II α (Top2a) mRNA, which appears to be inversely correlated to mmu-miR-672 expression, was significantly upregulated at ST and downregulated at LT. An inversion in the pattern of transcription-related mRNA-miRNA modulations was shown at LT exposure to allergens. From these findings, it can be speculated that the potential role of miRNAs in the modulation of transcription mechanisms would mostly consist in a fine-tuning process rather than striking regulations.

Cell cycle. MiRNA targeting genes regulating cell cycle are clearly downregulated at ST, not affected at IT and upregulated at LT. GMNN, which negatively regulates cell cycle, and MKI67, which is an endogenous marker of proliferative cells, are putative targets of mmu-miR-483. The expression of CCNB1 (cyclin B1) that activates CDK1 driving G2/M-phase progression [67], of CDCA8 (borealin) that is required for the proper segregation of chromosomes during mitosis [68] and of NUSAP1 that is selectively expressed in proliferative cells and is a positive regulator of mitosis by acting on microtubules organization [69] were significantly inversely correlated to mmu-miR-574-5p

as compared to the PBS-treated mice while the levels of mmu-miR-223 and -146b were increased. Their putative targets in this biological process embrace direct transcription initiator (TOP2A, topoisomerase II α), transcription factors (ZFP451, BTF3, KLF13 and TCFCP2L1), transcription coactivators (LPIN2) or corepressors (FOXP4, GMNN, PHB2) and proteins playing roles in functional organization of chromosome structure through chromatin remodeling (ARID4B).

We also observed that the mRNA potentially targeted by mmu-miR-223 (Arid4b, Lpin2, see Figure 5) and mmu-miR-146b (Zfp451, Klf13 and Tcfcp2l1) did undergo a downregulation at ST. This effect could be reinforced by the downregulation of mmu-miR-672, which potentially targets PHB2, a factor that restrains estrogen action and its activating pathway [65] and by repression of mmu-miR-483 that could be responsible for the observed upregulation of GMNN, an inhibitor of HOX-dependent transcriptional activity [66]. However, topoisomerase II α (Top2a) mRNA, which appears to be inversely correlated to mmu-miR-672 expression, was significantly upregulated at ST and downregulated at LT. An inversion in the pattern of transcription-related mRNA-miRNA modulations was shown at LT exposure to allergens. From these findings, it can be speculated that the potential role of miRNAs in the modulation of transcription mechanisms would mostly consist in a fine-tuning process rather than striking regulations.

Cell cycle. MiRNA targeting genes regulating cell cycle are clearly downregulated at ST, not affected at IT and upregulated at LT. GMNN, which negatively regulates cell cycle, and MKI67, which is an endogenous marker of proliferative cells, are putative targets of mmu-miR-483. The expression of CCNB1 (cyclin B1) that activates CDK1 driving G2/M-phase progression [67], of CDCA8 (borealin) that is required for the proper segregation of chromosomes during mitosis [68] and of NUSAP1 that is selectively expressed in proliferative cells and is a positive regulator of mitosis by acting on microtubules organization [69] were significantly inversely correlated to mmu-miR-574-5p
Table 4. Prediction of the mRNA targets for miRNA regulated at 2 time-points in the mouse model of asthma.

| MMU-miRNA | Targeted mRNA | MicroCosm Targets | Associated Biological process |
|-----------|---------------|-------------------|------------------------------|
|           | FI            | FI                | P-VALUE                      |                              |
| miR-223   | ARID4B        | 0.64 ST           | 0.0009                       | Transcription regulation     |
|           | ARID4B        | 19.70 IT          |                              |                              |
|           | CFLAR          | 0.66 ST           | 0.0068                       | Apoptosis                    |
|           | CFLAR          | 4.44 IT           |                              |                              |
|           | IL6            | 0.47 ST           | 0.0110                       | Inflammation                 |
|           | IL6            | 2.00 IT           |                              |                              |
|           | LPIN2          | 0.57 ST           | 0.0050                       | Transcription regulation     |
|           | LPIN2          | 2.14 IT           |                              |                              |
| miR-690   | 2010001M09RIK | 6.06 ST           | 0.0283                       | Apoptosis                    |
|           | 2010001M09RIK | 2.00 IT           |                              |                              |
|           | CDCCA8         | 3.03 ST           | 0.0472                       | Cell cycle                   |
|           | CDCCA8         | 1.87 IT           |                              |                              |
|           | CTSE           | 1.57 ST           | 0.0092                       | Immune response              |
|           | CTSE           | 2.73 IT           |                              |                              |
|           | FST            | 1.87 ST           | 0.0008                       | Cell differentiation         |
|           | FST            | 2.64 IT           |                              |                              |
| miR-29c   | COL6A2         | 1.80 IT           | 0.0000                       | Extracellular matrix         |
|           | COL6A2         | 1.87 IT           |                              |                              |
|           | CTSK           | 1.87 IT           | 0.0007                       | Protein metabolism           |
|           | CTSK           | 1.80 IT           |                              |                              |
|           | METRN1         | 2.30 IT           | 0.0041                       | Cell differentiation         |
|           | METRN1         | 1.62 IT           |                              |                              |
| miR-483   | GMNN           | 1.62 ST           | 0.0455                       | Transcription regulation     |
|           | GMNN           | 0.55 IT           |                              |                              |
|           | MKI67          | 2.64 ST           | 0.00147                      | Cell division                |
|           | MKI67          | 0.45 IT           |                              |                              |
|           | NOLA2          | 1.74 ST           | 0.0300                       | Ribosome biogenesis          |
|           | NOLA2          | 0.55 IT           |                              |                              |
|           | UBE2C          | 2.46 ST           | 0.0012                       | Protein metabolism           |
|           | UBE2C          | 0.39 IT           |                              |                              |
| miR-574-5p| CCNB1          | 4.76 ST           | 0.0339                       | Cell cycle                   |
|           | CCNB1          | 0.10 IT           |                              |                              |
|           | CDCCA8         | 3.03 ST           | 0.0006                       | Cell cycle                   |
|           | CDCCA8         | 0.35 IT           |                              |                              |
|           | DERA           | 1.57 ST           | 0.0058                       | Nucleotide synthesis         |
|           | DERA           | 0.66 IT           |                              |                              |
|           | NUSAP1         | 2.00 ST           | 0.0477                       | Cell cycle                   |
|           | NUSAP1         | 0.28 IT           |                              |                              |
| miR-672   | CD3G           | 1.74 ST           | 0.0054                       | Immune response              |
|           | CD3G           | 0.32 IT           |                              |                              |
|           | PHB2           | 1.68 ST           | 0.0042                       | Transcription regulation     |
|           | PHB2           | 0.66 IT           |                              |                              |
|           | PPP1R14B       | 1.74 ST           | 0.0069                       | Cell signalling              |
|           | PPP1R14B       | 0.62 IT           |                              |                              |
|           | TOP2A          | 2.46 ST           | 0.0037                       | Transcription regulation     |
|           | TOP2A          | 0.29 IT           |                              |                              |

The rationale for calculation (MicroCosm Target algorithm) is based on sequence complementarity between miRNA and the 3'UTR of its potential target, and on the inverse correlation of their regulation. The associated biological processes are also indicated. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t004
expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005

expression. These correlations reinforce the hypothesis that cell proliferation predominates at the early stages of asthma development rather than in the late stage and might probably partly be under miRNA control, especially through mmu-miR-29c expression. MiR-146c is upregulated and predicted targeted miRNA are downregulated at each time-point. ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.

doi:10.1371/journal.pone.0016509.t005
TNFSF9 by mmu-miR-146b could therefore play a central function in the evolution of the disease.

Another aspect of cell function appeared to be modulated by mmu-miR-146b. NUMB expression is inhibited by miR-146a in various cell lines [81]. NOTCH and NUMB controls the proliferative/differentiation balance in development and homeostasis. An increased degradation of NUMB, that antagonizes the cell surface receptor NOTCH, leads to uncontrolled cell proliferation in human mammary gland tumors [82]. Hyperplasia is also a characteristic of remodelling of airway walls and concerns epithelial cells, smooth muscle cells, fibroblasts and goblet cells. A decrease in NUMB at ST should result in substantial increase of cell proliferation. In the LT protocol, a downregulation of WDR12, another putative target of mmu-miR-146b, was also observed. This factor is involved in differentiation processes related to NOTCH signalling [83]. Therefore, mmu-miR-146b probably controls some aspect of cell proliferation and may participate in the development of subepithelial fibrosis in asthma, by regulating NUMB and WDR12 expression in the NOTCH signalling pathway.

MiRNAs modulation in different mice models of asthma was significantly associated with four signalling pathways

A large scale unbiased approach to determine the significance of the observed regulations of miRNA expression was also used. At each time-point, a set of predicted mRNA targets was identified for each miRNA significantly up- or downregulated above 1.5 fold. The use of a cut-off threshold of 1.5 on the fold-change is not uncommon in the context of miRNA profiling studies [84-86]. Since a single miRNA has several targets, moderate modifications of its expression may have deep impact at a cellular level. Moreover for studies profiling miRNA in complex tissues, such as lung in this study, a cut-off of 1.5 is more appropriate to identify regulations affecting only subpopulation of cells and not the entire organ. Based on the known functions of the protein encoded by these mRNA, pathways of regulation affecting behaviour and partly controlled by miRNAs can be identified. In order to further strengthen the analysis, two different databases were used. Target
prediction by MicroCosm Targets database is performed on optimal sequence complementarity between a set of mature miRNAs and a given mRNA using an algorithm reflecting the weight of each base position and allowing mismatches at the 5' end of miRNA [87]. Target prediction by TargetScan database is established on sequence complementarity to target sites with emphasis on perfect base-pairing in the seed region and on sequence conservation among species [88].

Sixteen pathways at ST, 25 at IT and 19 at LT were selected with a combined p-value of 0.05 (Tables S5, S6 and S7) with MicroCosm Targets database and 16 pathways at ST, 21 at IT and 32 at LT were selected with a combined p-value of 0.05 (Tables S8, S9 and S10) with TargetScan database. The comparison of these data highlighted four common pathways that are modulated at the three time-points (Figures 7 and 8). Matching results from the two algorithms allowed us to select signalling pathways strongly involved in the development of asthma. Some interactions between modulated miRNAs and their potential targets are discussed below.

**Matrix Metalloproteinases Pathway.** Matrix Metalloproteinases (MMPs) Pathway (WP441) was the most significantly modified by the miRNA modulation at the three time-points (p-value < 0.01), which confirms our previous transcriptomic analysis [4]. MMPs and their inhibitors (tissue inhibitors of matrix metalloproteinases, TIMPs) contribute to the pathogenesis of asthma by regulating the cleavage of peptidic mediators that influence the functions and the migration of inflammatory cells and by modifying the extracellular matrix homeostasis. Apart from their role in acute airway inflammation, MMPs may contribute to features of airway remodelling including reorganization of matrix, angiogenesis and smooth muscle hyperplasia.

At ST, a decrease in mmu-miR-203 and -1 expression is expected to induce the upregulation of MMP-24 and TIMP-3 (Figure 9). At IT, repression of mmu-miR-29b and -29c should induce an increase expression of MMP-15 and -24 (Figure 4A-D) but also of MMP-2. Moreover, these miRNAs can prospectively target MMP-2 and MMP-15. Finally, at LT, TIMP-2 and TIMP-

---

**Figure 4. Dose-response analysis of the effect of miR-29b, -29c and -146b on their predicted target in lung cells.** Transient transfection analysis for luciferase reporter expression with mouse Mmp-15 3'UTR in the presence of miR-29b and -29c (Panel A); mouse Mmp-24 3'UTR in the presence and absence of miR-29b and -29c (Panel B); human Mmp-15 3'UTR in the presence of miR-29b and -29c (Panel C); human Mmp-24 3'UTR in the presence of miR-29b and -29c (Panel D); mouse C06a2 3'UTR in the presence of miR-29c (Panel E); mouse Ctsk 3'UTR in the presence of miR-29c (Panel F); mouse Scube2 3'UTR in the presence of miR-146b (Panel G); mouse Card10 3'UTR in the presence of miR-146b (Panel H). Universal negative siRNA was used at 20 nM as non-functional small RNA control. For each expression vector, the specific effect of the miRNA on luciferase activity was expressed as compared to the activity measured in the control condition, arbitrarily set at “100”. Results are expressed as mean ± SD. (* p-value < 0.05; ** p-value < 0.001; # p-value < 0.005).

doi:10.1371/journal.pone.0016509.g004

**Figure 5. Analysis of 13 miRNAs-predicted target murine genes in vitro.** Transient transfection analysis for luciferase reporter expression with Arid4b, Il-6 or Lpin2 3'UTR in the presence of miR-223; with Gmnn, Nola2 or Ube2c 3'UTR in the presence of miR-483; with Dera or Nusap1 3'UTR in the presence of miR-574-5p; with Cd3g or Phb2 3'UTR in the presence of miR-672; and with Fst, Ctske or Cdca8 3'UTR in the presence of miR-690. Universal negative siRNA were used at 20 nM as non-functional small RNA control. For each expression vector, the specific effect of the miRNA on luciferase activity was expressed as compared to the activity measured in the control condition, arbitrarily set at “100”. Results are expressed as mean ± SD. Each p-value is indicated in the graph.

doi:10.1371/journal.pone.0016509.g005
3 mRNAs are the predicted targets of several modulated miRNAs (mmu-miR-30b, -30c, -30d, -21, -214 and -206).

Deregulation of TIMPs and MMPs activities can lead to an exaggerated matrix turnover and be responsible for subepithelial fibrosis observed in asthma. A common feature of MMP-15 and MMP-24 is that they are membrane-type MMPs sharing an identical substrate, the pro-MMP-2. In lung fibrosis, in the late stages of the disease, MMP-2 may be associated to pathological collagen deposition and interstitial fibrosis [89]. Since no significant modifications in MMP-2, MMP-15 and MMP-24 mRNA levels were observed [4], it strongly suggests that miRNAs regulate the translation of these MMPs [11]. This hypothesis is further reinforced by our functional data showing that 3’UTRs of both human and mouse Mmp-15 and -24 are similarly targeted by miR-29b and -29c. Finally these results are in line with those of Henderson et al. [90] describing post-transcriptional regulation of MMP-2 and TIMP-2 protein levels and demonstrating a sharp increase in MMP-2 activation during airways remodelling in asthma.

TIMPs are key regulators of the activity of many metalloproteinases including MMPs, ADAMs and ADAMTS. TIMP-1 mRNA upregulation during lung fibrosis has already been described as TIMP-2 and TIMP-3 mRNA were shown to be constitutively expressed [4,89]. TIMP-2 not only inhibits MMP-2 activity but is also involved in docking pro-MMP-2 to the cell surface where the enzyme is activated [91] by membrane-bound MMPs, including MMP-15 and MMP-24 [92], and by a second molecule of TIMP-2. TIMP-3 binds to the extracellular matrix

**Figure 6. Potential influence of miRNAs on immune response induced by OVA.** In antigen presenting cells, MHC complexes are maturated in endosomes by lysosomal reductases while CTSE processes antigen (Ag), i.e. OVA. Finally, the MHC/antigenic peptide complex translocates to the plasma membrane and is presented to the TCR/CD3 complex on CD4+ T helper cell surface. Activation of TCR/CD3 induces the activation of NF-κB through PKC activation and CARD11/BCL10/MALT1 complex recruitment. MiRNA modulation could occur through mmu-miR-690, -672 and -146b. Cross-linking of costimulatory receptors on the T helper cell with corresponding ligands, such as TNFRSF9 with TNFSF9, also induces NF-κB and regulators (MAPKs, JNK) of the activity of multiple transcription factors. Production of TNFSF9 could be under the control of mmu-miR-146b, thus regulating the T helper cells properties. ST, IT, LT: short, intermediate and long-term treatments, respectively. The observed up- and down-regulations of the expression of some specific miRNAs are reported. doi:10.1371/journal.pone.0016509.g006
and may be important in allowing excess matrix accumulation in asthmatic airways [93]. At LT, 6 different miRNAs potentially targeting TIMP-2 and TIMP-3 are significantly up or downregulated which is highly susceptible to affect the complex array of interactions between MMPs and their targets (extracellular matrix macromolecules, cytokines...) and may represent a crucial regulatory switch during asthma disease.

**Androgen Receptor Signalling Pathway.** Several miRNAs regulated in asthma target mRNAs that are implicated in the Androgen Receptor Signalling Pathway (WP252). Although it could seem surprising, cross-talk between this pathway and regulatory cascades originating from growth factors (IGF1, FGF2, EGF, TGFβ) are well documented. In prostate and lung, they have been shown to regulate several cell functions with direct implication in chronic asthma (such as apoptosis, survival, proliferation and differentiation [94,95]).

IGF1 is known to increase fibroblast survival and growth, and to be an important mediator of inflammation and remodelling in the asthmatic airways, as well as an inducer of bronchial smooth muscle contraction [96,97]. We had previously shown that IGF1 mRNA is strongly upregulated at ST, IT and LT [4]. This may be due to transcriptional regulation [98] but possibly also to the repression of miRNAs (mmu-miR-1 at ST; mmu-miR-450a-5p at IT; mmu-miR-27a and -92a at LT) that target IGF1 mRNA. Constant upregulation of mmu-miR-146b could also influence changes that occur in the complex IGF1-dependent regulatory cascades.
In this study, we also underlined the importance of interactions between modulated miRNAs during mouse model of asthma and transcription factors (SP1, POU2F2, PATZ1...), receptors (NRIP, NR3C1...), nuclear receptor co-factors (NCOR2, NCOA1, NCOA3, PIAS1, PIAS3, NROB1, PNRC1...) or signal transducers (IL6ST, RAN...) participating in the Androgen Receptor Signalling Pathway. These evidences support the hypothesis that, besides transcription factors only, miRNA or miRNA/transcription factors networks participate in the control of this pathway and of the release of IGF1.

**Inflammatory Response Pathway.** Recent reviews [99,100] have shown evidence that miRNAs play a role in the control of inflammation cascades and particularly in cytokines regulation. Tumour necrosis factor-alpha (TNFα) promotes inflammation and airway remodelling. It is intensely released in asthmatic airways by pro-inflammatory cells, including activated macrophages, but also by structural cells [101]. Its elevated levels in asthmatic patients seem mainly due to a massive release of the preformed cytokine [102] rather than to an increased transcription. No correlation between miRNA modulation and TNFα was made in this study. By contrast, the expression of its two main receptors, TNFRSF1A (TNF-R1) and TNFRSF1B (TNF-R2), is expected to be upregulated at ST and IT as a result of the downregulation of mmu-miR-690, -805 and -574-5p (at ST) and mmu-miR-29b, -29c, -152, -218 and 690 (at IT). This would...
induce an enhanced receptor production and accumulation at cell surface, and could contribute to an amplification of this regulatory cascade, in synergy with the massive release of TNFα. At LT, mmu-miR-29c and -98 are downregulated but upregulation of mmu-miR-125b-5p and -574-5p, and progressive normalization of the levels of mmu-miR-218, -690 and -805 would then be part of the reduction of the inflammatory process at the late stage of the asthma model through the modulation of TNFα receptors.

Downregulation of mmu-miR-29 members is strongly correlated with Inflammatory Response Pathway (WP458) especially with the extracellular matrix components directly involved in fibrosing processes. These miRNAs are speculated to regulate the expression of type I and type III collagens but also the laminin γ chain LAMC1. Evidence that miR-29b attenuates expression of collagen genes by blocking their mRNA translation has already been described [103,104] and an inverse correlation between the expression of mmu-miR-29b and -29c and the synthesis of collagen type I and III is further evidenced here. This suggests that downregulation of mmu-miR-29 members could be one of the causes of the subepithelial fibrosis observed in chronic asthma.

Fibronectin (FN1) is present in large quantities in fibrosing areas [105], precedes collagen type I deposition and is necessary for pulmonary fibrosis to develop [106]. Surprisingly however, its mRNA is only slightly upregulated at IT and not at ST or LT [4]. This apparent discrepancy can probably be explained by the decrease of the post-transcriptional repression by miRNAs at each step of the progression of the disease [107-109]. Here we showed that several modulated miRNAs could potentially target Fn1 mRNA at the three time-points. All of them were downregulated: mmu-miR-1 and -805 at ST, mmu-miR-199a-3p, -200a and -429 at IT and mmu-miR-27a and -200b at LT, except mmu-miR-206 which was upregulated at LT. Together with collagens and fibronectin, laminin is another key component of the extracellular matrix that is exceedingly accumulated in airway walls during remodelling processes in patients with severe bronchial asthma [110]. In this mouse model of asthma, various laminin chains (LAMA5, LAMB1, LAMC1 and LAMC2) expressions were predicted to be affected by many miRNAs. However, there is no clear tendency at ST and LT where targeting miRNAs are up- or downregulated in equal proportions. At IT, expressions of mmu-miR-29b, -29c, -152, -200a and -690 that potentially target laminin γ chain LAMC1 are inhibited.

The miRNAs implication in the regulation of the Inflammatory Response Pathway appears to occur principally through the
regulation of extracellular matrix component expression rather than through the modulation of cytokines and their receptors, except for the TNF-α receptors.

**IL-3 Signalling Pathway.** *In silico* analysis predicted IL-3 Signalling Pathway (WP373) as regulated by miRNAs. Eosinophils activated by IL-3 contribute to T cell activation in allergic diseases [111] and play a critical role in the induction of airway hyperreactivity and the development of lesions that underpin chronic airway wall remodelling [112].

IL-3 induces transient association between paxillin (PXN) and vinculin (VCL), two cytoskeletal proteins necessary for the contractile response of smooth muscle cells as observed during asthma [113]. During the whole time course of the model, PXN is a potential target of several downregulated (mmu-miR-203, -218, -30b, -30c, -27a and -21) and upregulated (mmu-miR-20b, -466g, -30d and -214) miRNAs. At IT and LT, VCL is a potential target of 5 downregulated miRNAs (mmu-miR-21, -25, -29b, -29c and -92a). Besides VCL binding, PXN interacts with SRC and CRK family members [114], which leads to proliferation and differentiation processes in fibroblasts through the MAPK pathway or regulates the formation of physical links between the cytoskeleton and integrin proteins that mediate transmission of contraction forces [115]. It is of interest that a large number of modulated miRNAs were pointed out to interact with SRC (mmu-miR-197 and -230), CRK and CRKL (mmu-miR-203, -497, -218, -320, -214, -328), and various MAPKs (4 miRNAs for MAPK1, 3, 8 and 14; 7 miRNAs for MAPK9; 13 miRNAs for MAPK7; see Tables S5-S10 for details).

IL-3 induces Toll-like receptors expression in dendritic cells [116] that then initiate the activation of T lymphocytes for specific antigens [117]. Genes implicated in Toll-like receptors signaling such as GSK3B (a glycogen synthase kinase), SOCS3 (a suppressor of cytokine signalling-3) and ATF2 (an activating transcription factor) were defined as targets of modulated miRNAs during all time-course of the mouse model of asthma, respectively mmu-miR-23a, -23b, -26b, -29b, -29c, -155 and -214 for Gsk3b; mmu-miR30b, -30c, -30d, -152, -203, -207, -218 and -455 for Atf2; mmu-miR30b, -30c, -30d, -152, -203, -207, -218 and -455 for Socs3.

YWHA proteins (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) act as adaptor proteins in cellular signaling and metabolism by regulating and coordinating a diverse array of cellular processes, such as cell cycle progression, apoptosis, protein trafficking, cytoskeleton rearrangements, metabolism, and transcriptional regulation of gene expression [118]. They can bind to GSK3 [119], implicated in Toll-like receptors...
signalling. For the three time-points, 23 modulated miRNAs (see Tables S5-S10 for details) could target mRNAs of three members of YWHA protein family: Ywhab, Ywhaq and Ywhaz. To our knowledge, the role of these proteins in asthma is not known.

The whole analysis for each time-point, including details on number of miRNA and miRNA-mRNA interactions in specific pathways is available in online supplemental data.

In conclusion, this work represents the first large scale study aiming at evaluating the implication of miRNAs during asthma, from early inflammation to chronically remodelled airways. Highly significant correlations between regulation of miRNAs expression and several biological processes or regulatory pathways have been found at each step of the evolution of allergen-induced asthma in mice. Similar results were obtained by comparing our data with two different databases using different computational analyses, further reinforcing the significance of this study. Although direct confirmation of the specific implication in vivo of the most promising miRNA-mRNA pairs have yet to be performed, the miRNAs profiling data described in the present work are new information allowing a better understanding of molecular mechanisms participating in this complex and progressive pathology and might lead to novel therapeutic approaches targeting either some specific miRNAs of the regulatory processes identified here.

Methods

Mouse model of asthma

BALB/c mice were used following “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research, and the experimental protocols were approved by the local animal ethical committee (University of Liège) under the no. 03/158. Six- to 8-week old BALB/c male mice were sensitized on days 1 and 7 or 11 (see below) by intraperitoneal injection of 10 μg of ovalbumin (OVA Grade III; Sigma-Aldrich, Schnelldorf, Germany) emulsified in aluminum hydroxide (AlumInject; Perbio, Erembodegem, Belgium). Animals were subsequently divided into 2 groups of six animals: 1 group of control mice was exposed to phosphate buffer saline (PBS) aerosol and the other experimental group was subjected to ovalbumin (OVA) aerosol 1% aerosol for 30 min. A three time-points, named “short-term” (ST), “intermediate-term” (IT) and “long-term” (LT), exposure protocol was designed to reproduce the airway hyperresponsiveness, the inflammation phase and the remodelling process observed during the course of asthma development. At day 21, aerosols were generated daily by ultrasonic nebulizer (DeVilbiss 2000) and performed for 7 consecutive days (ST protocol). For IT or LT protocols, aerosols were performed three (IT) or five (LT) times according to a pattern of 5-day inhalation followed by a 9-day time off. After determination of airway reactivity, mice were sacrificed by cervical dislocation the day after last aerosol challenge. The experimental protocols are illustrated in Figure 10.

Lung tissue processing and RNA extraction

For each time-point experiment (ST, IT or LT), PBS-treated (n = 6) and OVA-treated (n = 6) mice were killed by cervical dislocation. Further to lung eosinophilia, differential cell counts were performed in bronchoalveolar lavages (BAL) in PBS- and OVA-treated mice. After sacrifice of mice, a cannula was placed in the trachea and a BAL was performed by gentle manual instillation and aspiration using 4×1 ml of 0.05 mM cold PBS-EDTA (Calbiochem, Germany). The BAL was centrifuged (250 g, 10 min, 4°C). The cell pellet was resuspended in 1 ml of PBS-EDTA. Total cells counts were obtained using a hemocytometer. The differential cell counts were performed using morphological criteria on cytocentrifuged preparations (Cytospin) after staining with Diff-Quick (Dade, Belgium). Differential cell counts were performed by one observer unaware of the various experimental conditions.

Immediately after BAL, the right lobe of the lung was stored in liquid nitrogen. The left lobe was used for histological assessment of airway remodeling histology as previously described [4].

Tissue disruption was performed with a Mikro-Dismembrator in liquid nitrogen and tissue powder (50 to 100 mg) was directly homogenized in 1 ml of Trizol reagent. Phase separation was performed according to reagent protocol. Total RNA was precipitated by an overnight incubation in 0.5 ml of isopropanol at −80°C. Centrifugation (12,000 g, 10 min, 4°C) was then performed and RNA pellet was washed twice by ethanol 75% and centrifugation (7,500 g, 5 min, 4°C). Total RNA pellet was briefly air-dried in a sterile hood, finally dissolved in RNase free water (50 to 100 μl) and stored at −80°C.

RNA quality control

Each total RNA sample concentration was determined using a NanoDrop ND-1000 spectrophotometer. The integrity of each total RNA extract was assessed with an Agilent 2100 Bioanalyzer and degraded samples were rejected. The passing criteria for use in miRNA microarray and quantitative real-time PCR was a 28S/18S rRNA ratio between 0.90 and 1.80 (maximum obtained). The presence of small RNA was evidenced by a clear peak at about 25 seconds.

miRNA microarray analysis

Microarray assay was performed using a service provider (LC Sciences, Houston, Texas). The assay started with 5 μg total RNA pools containing equal amount of RNA from individual lung (n = 6 per pool), which was size-fractionated using a YM-100 Microcon centrifugal filter (Millipore, Billerica, MA), and the isolated small RNAs (<300 nt) were 3’-extended with a poly(A) tail using poly(A) polymerase. An oligonucleotide tag was then ligated to the poly(A) tail for later fluorescent dye staining (Cy3 and Cy5 were used for the two RNA pools, OVA versus PBS for each time-point, in a duplicate experiment). Hybridization was performed overnight on a μParaflod microfluidic chip using a microcirculation pump (Atactic Technologies, Houston, TX) [120]. On the microfluidic chip, each detection probe consisted of a chemically modified nucleotide coding a segment complementary to target microRNA (with mice probe content from miRBase, version 10.0, http://microrna.sanger.ac.uk/sequences/) or other control RNA, and a spacer segment of polyethylene glycol to extend the coding segment away from the substrate. The detection probes were made by in situ synthesis using photogenerated reagent chemistry.

Hybridization used 100 μl 6× SSPE buffer (0.90 M NaCl, 60 mM Na₂HPO₄, 6 mM EDTA, pH 6.8) containing 25% formamide at 34°C. After RNA hybridization, tag-conjugating microarray scanner (GenePix 4000B, Molecular Devices, Sunnyvale, CA) and digitized using Array-Pro image analysis software (Media Cybernetics, Bethesda, MD). Data were analyzed by first subtracting the background and then normalizing with a cyclic LOWESS filter (Locally-weighted Regression) [121]. For two color experiments (OVA versus PBS pools for each time-point), the ratio (log transformed) of the two sets of detected signals, and p-values of the t-test, were calculated. Differentially detected signals was accepted as true when the ratios of the p-value was less than 0.01. Results were finally given in terms of “fold induction”.

In conclusion, this work represents the first large scale study of airway remodeling histology as previously described [4].
Real-time quantitative RT-PCR validation

In order to reassess the reproducibility of our mouse model asthma and to use in this study the previously described transcriptomic data [4], the expression of 8 genes regulated at least at one time-point was measured for each individual mouse. Total RNA (1 μg) was reverse transcribed using random primers (Europetgen, Belgium) and SuperScript III Reverse Transcriptase (Invitrogen) according to manufacturer’s protocol. cDNAs were then subjected to real time PCR using SYBR Green qPCR Mastermix buffer (Eurogentec, Belgium). Primers used to amplify Ccl8, Fcgr2b, Chia, Birce5, Cdc2a, Pon1, Arg1 and Mmp-12 have been previously described [4]. Expression levels of each miRNA were evaluated using comparative threshold cycle (Ct) method, normalized to those of β2-microglobulin and hypoxanthine guanine phosphoribosyl transferase 1 (house-keeping genes) for each condition (delta Ct). Experiments were done at least in duplicate. The fold change of each miRNA was calculated as a difference between mean values obtained for OVA- and PBS-treated mice at each time-point (delta delta Ct). The fold difference in expression was calculated using the 2^{-delta delta Ct} method. Mean values of fold difference for each cohort used here were compared to those obtained previously [4] (Figure S1).

In order to validate miRNA microarray analysis and to evaluate inter-individual variation in each group of mice, real-time quantitative RT-PCR assays (QuantiMir RT Kit Small RNA Quantitation System, SBI System Biosciences, USA) were done on individual lung RNA sample to confirm the differential expression of 14 miRNAs. The selection of the miRNAs is based on their potential role in the pathology of the lung (mmu-miR-1, 146b, -203, -21, -223, -29b, -29c) or on their high and significant differential expression in the model (mmu-miR-455, -574-5p, -672, -690) or for their high (mmu-let-7b a, mmu-miR-145) or low (mmu-miR-450a-5p) signal intensity in microarray analysis. The protocol is based on poly(A) tailing and reverse transcription of small non-coding RNAs to provide cDNA synthesis of miRNA. A universal 3’-tag sequence is incorporated during reverse transcription to enable miRNA expression analysis by quantitative PCR. The reverse sense primer is universal and provided by the kit. The forward sense primer is designed by using the sequence of the mature miRNA (5’-19 nucleotides) converted in DNA sequence (Table 6). Forward LNA primers (Exiqon, Denmark) were used to amplify mmu-miR-146b, -29b and 29c in order to increase specificity and discrimination that were not obtained with native DNA primers. Reactions are performed following manufacturer’s protocol with 2 μg of total RNA and SYBR Green qPCR Mastermix buffer (Eurogentec, Belgium). Expression levels of each mature miRNA were evaluated using comparative threshold cycle (Ct) method, normalized to those of U6 small nuclear RNA (house-keeping gene) for each condition (delta Ct). The fold change (OVA-PBS means) of each miRNA was calculated and expressed as 2^{-delta delta Ct}. Mean values of fold difference for each cohort were compared to mean values obtained for pools analyzed by microarray hybridization.

miRNA microarray analysis

Microarray raw miRNA expression data were from [4] and are in full agreement with RT-qPCR data obtained in this study for new cohort of mice. Probe-level data was background-adjusted and normalized, and gene expression measurements were obtained with the robust multi-array average (RMA) method [122], as implemented in the Affy package of Bioconductor. For each of the three time points, the gene expression log ratios were computed between the PBS control and from two different OVA-treated pools. Genes with a mean OVA/PBS log ratio more than 0.6 or less than −0.6 were selected as up-regulated or down-regulated, respectively. These values correspond to genes regulated 1.32-fold up or down.

When more than one expression value was present for a gene (multiple probe sets per gene), the gene was considered up- or down-regulated if the direction of change (up/down) was consistent between all probe sets, and at least one of the probe sets satisfied the -0.6/0.6 threshold on log ratios.

miRNA-mRNA correlation analysis

Potential correlations between miRNAs and mRNAs regulated at each time-point were determined by crossing the lists of modulated miRNAs and miRNAs with a database of miRNA target predictions. The list of candidates mRNA targets for each miRNA was retrieved from the MicroCosm Targets database Version 5 (http://www.ebi.ac.uk/enright-srv/microcosm), formerly known as mirBase::Targets [12], that uses the miRanda algorithm [123] to identify potential binding sites for a given miRNA in gene sequences. All modulated miRNAs were represented in this database.

Fifteen modulated genes (among 1955 in total) were not predicted as targets of any miRNAs.

Table 6. Mature miRNA sequences and forward primers sequences for real-time quantitative PCR.

| miRNA     | miRNA Base #    | miRNA sequence                                   | Forward primer sequence |
|-----------|-----------------|-------------------------------------------------|-------------------------|
| mmu-let-7b| MIMAT0000522    | 5’- uggggugagccauuuguaaccc - 3’                 | 5’'- tggaggtagttggtgctg - 3’ |
| mmu-miR-1 | MIMAT000123     | 5’- uggagauggaaagaaagauag - 3’                 | 5’'- tgaaggttgtagttgctg - 3’ |
| mmu-mir-145| MIMAT000157    | 5’- guccaguuuucgcagguaucccc - 3’              | 5’'- gtcgaatttttgagcaaat - 3’ |
| mmu-mir-203| MIMAT000236    | 5’- guggauauuggacagcacac - 3’                 | 5’'- gtaaatgtgtgacagcacac - 3’ |
| mmu-mir-21 | MIMAT000530     | 5’- uaggcaacacagugauugua - 3’                 | 5’'- tagsctagctacagttgt - 3’ |
| mmu-mir-223| MIMAT000665    | 5’- ugucaauuucgcacaaaccc - 3’                 | 5’'- tggctagttgctaatc - 3’ |
| mmu-mir-450a-5p| MIMAT0001546 | 5’- uugggcagauuugaccaau - 3’                | 5’'- tttttgatgtgtttccaa - 3’ |
| mmu-mir-455| MIMAT0003742   | 5’- gacagacaggccauuuac - 3’                 | 5’'- gagctagcggccatatac - 3’ |
| mmu-mir-574-5p| MIMAT0004893 | 5’- uggagggugucaggggugugug - 3’            | 5’'- tggagtgtgtgtgtgag - 3’ |
| mmu-mir-672| MIMAT0003735   | 5’- uggagguuggccuguugugug - 3’               | 5’'- tggagagttgtagctgt - 3’ |
| mmu-mir-690| MIMAT0003469   | 5’- aagggcucgcacacacac - 3’                  | 5’'- aagggcagtggccacacac - 3’ |

doi:10.1371/journal.pone.0016509.t006
At each time-point, we determined all the miRNA-mRNA pairs such that the miRNA is predicted as a potential target of the miRNA and the miRNA and the mRNA are differentially expressed in opposite direction, i.e. the miRNA is down-regulated and the mRNA is up-regulated, or the opposite. Tables S2, S3, and S4 list all these pairs respectively at ST, IT and LT. The p-values in these tables are the p-values associated with the target prediction as described in [124] (only targets with a p-value lower than 0.05 are included in the MicroCosm Targets database).

Pathway analysis
A pathway enrichment analysis was carried out taking into account both modulated miRNAs and mRNAs. A list of 117 pathways was downloaded from WikiPathways (http://www.wikipathways.org, [125]). Predicted candidates mRNA targets for each differentially expressed miRNA were identified using two databases: MicroCosm Targets Version 5 (http://www.ebi.ac.uk/enright-srv/microcosm) and TargetScan Version 4.2 (http://www.targetscan.org).

For each pathway and each time-point, a p-value reflecting the enrichment of the pathway in modulated miRNA targets (with at least 1.5-fold, up or down) was computed as follows: we counted the total number of miRNA-gene pairs such that the miRNA is modulated, the gene belongs to the pathway and is a potential target of the miRNA. A p-value was then associated to this number by computing the proportion of times (estimated from 1000 trials) a purely random selection of the modulated miRNAs (among the 566 miRNAs on the chip) gives a number of pairs as high as the

Table 7. Genes, species and their amplified 3'UTRs with corresponding primers.

| Gene | Species | 3'UTR size* | Forward Primer | Reverse Primer |
|------|---------|-------------|----------------|----------------|
| Arid4b | M. musculus | 2385 | GCCGTTAATCTAGA-acaacaaaaaggggaaaggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Card10 | M. musculus | 1727 | GCCGTTAATCTAGA-gagggattcagaaaggaagtc | GTCTGCTCAGAACGGG-tctatgcaactttaatgacttattttg |
| Cd3g | M. musculus | 603 | GCCGTTAATCTAGA-tggaaactttggaattttca | GTCTGCTCAGAACGGG-tagttactaatcattttttttgtca |
| Cdc8 | M. musculus | 786 | GCCGTTAATCTAGA-ctccccccttctttttaact | GTCTGCTCAGAACGGG-gcttttaaactttggaactttactc |
| Col6a2 | M. musculus | 849 | GCCGTTAATCTAGA-tgggctcgttcttactttttacttt | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Cte | M. musculus | 980 | GCCGTTAATCTAGA-tgccctggatggaatcc | GTCTGCTCAGAACGGG-gacttaaaaccatggcaaactaaga |
| Ctsk | M. musculus | 759 | GCCGTTAATCTAGA-tggaaaactgcattgagctaaa | GTCTGCTCAGAACGGG-gagtttactaatcattttttttgtca |
| Dera | M. musculus | 848 | GCCGTTAATCTAGA-gccctggatggaatcc | GTCTGCTCAGAACGGG-gacttaaaaccatggcaaactaaga |
| Fst | M. musculus | 1410 | GCCGTTAATCTAGA-tgggctcgttcttactttttacttt | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Gmnn | M. musculus | 980 | GCCGTTAATCTAGA-ccctcctgctgaggtgag | GTCTGCTCAGAACGGG-gacggaggaagttttttaaaagtgg |
| Il6 | M. musculus | 1090 | GCCGTTAATCTAGA-gtccctccttactttttacttt | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Lpin2 | M. musculus | 3069 | GCCGTTAATCTAGA-caggtccagaagtgtagtttag | GTCTGCTCAGAACGGG-gcttttaaactttggaactttactc |
| Mmp-15 | M. musculus | 1772 | GCCGTTAATCTAGA-gccggtgctgagggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Mmp-15 | H. sapiens | 1439 | GCCGTTAATCTAGA-taaccggggttcggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Mmp-24 | M. musculus | 2353 | GCCGTTAATCTAGA-caggtccagaagtgtagtttag | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Mmp-24 | H. sapiens | 2318 | GCCGTTAATCTAGA-gccggtgctgagggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Nola2 | M. musculus | 1004 | GCCGTTAATCTAGA-gccggtgctgagggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Nusap1 | M. musculus | 1400 | GCCGTTAATCTAGA-gccggtgctgagggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Phb2 | M. musculus | 640 | GCCGTTAATCTAGA-gccggtgctgagggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Scube2 | M. musculus | 836 | GCCGTTAATCTAGA-gccggtgctgagggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |
| Ube2c | M. musculus | 931 | GCCGTTAATCTAGA-gccggtgctgagggg | GTCTGCTCAGAACGGG-gaatttacctccctttttacg |

*Size (bp) of amplified 3'UTRs for each target.

doi:10.1371/journal.pone.0016509.t007
observed one. A p-value reflecting the enrichment of the pathway in modulated mRNAs was computed from the number of modulated genes in the pathway using the hypergeometric distribution (using the set of 20461 genes of the chip as a reference set). For this analysis, the set of modulated genes was defined as the set of genes with a fold induction greater than 1.5 in both experiments. A unique p-value was finally associated to each pathway by combining the miRNA and mRNA p-values using Stouffer’s method [126].

Functional validation

Cell Culture and Reagents.  SV40-transformed human lung fibroblasts WI26 were grown in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% FBS (Lonza). All cells were incubated at 37°C in a humidified chamber supplemented with 5% CO₂.

Plasmid constructs. The luciferase-UTR reporter plasmids were constructed by introducing 3’UTR of 21 genes carrying putative miRNA binding sites into pGL3-promoter vector that contains an SV40 promoter upstream of the luciferase gene (#E1761, Promega). 3’UTR sequences were amplified from WI26 cDNA (for human 3’UTRs) and from total lung Balb/c mice cDNA (for murine 3’UTRs) by PCR (see Table 7 for amplified 3’UTRs and primers) using the Easy-A® One-Tube RT-PCR System (#600182, Agilent Technologies-Stratagene Products). After double digestion by FseI and XbaI of the pGL3-promoter vector (#E1761, Promega), the 3’UTRs were cloned into this vector using the In-Fusion cloning kit (#639619, ClonTech). The correct insertion of these 3’UTRs into the pGL3-promoter vector was verified by restriction analysis and sequencing.

Table 8. Targeted 3’UTR sequences, corresponding miRNA Mimic and concentrations used.

| GENE     | mSCRIPT miRNA MIMIC | CONCENTRATIONS |
|----------|----------------------|----------------|
| Arid4b   | Syn-hsa-miR-223      | 20 nM          |
| Card10   | Syn-hsa-miR-146b     | 2.5, 5, 10, 20, 30 nM |
| C3d3g    | Syn-hsa-miR-672      | 20 nM          |
| Cdc4a8   | Syn-hsa-miR-690      | 20 nM          |
| Col6a2   | Syn-hsa-miR-29c      | 2.5, 5, 10, 20, 30 nM |
| Ctsc     | Syn-hsa-miR-690      | 20 nM          |
| Ctsk     | Syn-hsa-miR-29c      | 2.5, 5, 10, 20, 30 nM |
| Dora     | Syn-hsa-miR-574-5p   | 20 nM          |
| Fst      | Syn-hsa-miR-690      | 20 nM          |
| Gmnn     | Syn-hsa-miR-483      | 20 nM          |
| B6       | Syn-hsa-miR-223      | 20 nM          |
| Lpin2    | Syn-hsa-miR-223      | 20 nM          |
| Mmp-15 (m, h) | Syn-hsa-miR-29b, Syn-hsa-miR-29c | 2.5, 5, 10, 20, 30 nM |
| Mmp-24 (m, h) | Syn-hsa-miR-29b, Syn-hsa-miR-29c | 2.5, 5, 10, 20, 30 nM |
| Nola2    | Syn-hsa-miR-483      | 20 nM          |
| Nusap1   | Syn-hsa-miR-574-5p   | 20 nM          |
| Phb2     | Syn-hsa-miR-672      | 20 nM          |
| Scube2   | Syn-hsa-miR-146b     | 2.5, 5, 10, 20, 30 nM |
| Ube2c    | Syn-hsa-miR-483      | 20 nM          |

(m, h): murine and human 3’UTRs.
doi:10.1371/journal.pone.0016509.0008

Transfection. WI26 cells were transfected using jetPRIME reagent (Polyplus transfection) following the manufacturer’s protocol for DNA and miRNA mimic cotransfection. In brief, 60,000 cells were seeded in a 24-well plate 24 hours prior transfection. They were transfected on the following day with 250 ng of plasmid DNA and with 2.5 to 30 nM miRNA mimic (mScript miRNA Mimic, Qiagen) (Table 8) or 20 nM AllStars Negative Control siRNA (Qiagen) per well. Transfection medium was then replaced by cell growth medium 24 hours after transfection.

Luciferase Assay. Luciferase assays were carried out in WI26 cells 40 hours after transfection as a way to determine the effect of microRNAs on the activity of Luc-3’UTRs. Cells were harvested, lysed and luciferase activity was determined by using Luciferase Reporter Gene Assay, high sensitivity (Roche Applied Science, Belgium) according to the manufacturer’s protocol. Protein quantification was used for normalization. Knockdown was calculated as a ratio comparing for each construct the luciferase activity measured in presence of the specific miRNA to the activity obtained in presence of the non-functional control.

Experiments were done at least in duplicate and data are presented as means ± SD. Statistical analyses were performed using unpaired two-tailed Student’s t-tests.

Supporting Information

Figure S1 mRNA expression profiles in our models of allergen-induced asthma. Validation of reproducibility of our models of allergen-induced asthma was assessed by comparing the mRNA level of a series of selected genes measured by RT-qPCR (in duplicate) on individual lung RNA in each group (ST, IT LT) of PBS- and OVA-treated mice to data obtained by microarray analysis in a previous study [4]. The graphs illustrate a concordance of 8 significantly modulated genes. mRNA levels were normalized by using β2-microglobulin and hypoxanthine guanine phosphoribosyl transferase transcripts. Differences (fold induction) between samples (OVA vs PBS) were calculated using the 2-delta delta Ct method. Results are expressed as mean ± SD. (TIF)

Table S1 Significantly modulated mature miRNAs and their respective fold induction for each time-point experiment. (DOC)

Table S2 Modulated mRNAs and inversely correlated modulated miRNAs at ST using MicroCosm Targets. (DOC)

Table S3 Modulated mRNAs and inversely correlated modulated miRNAs at IT using MicroCosm Targets. (DOC)

Table S4 Modulated mRNAs and inversely correlated modulated miRNAs at using MicroCosm Targets. (DOC)

Table S5 MiRNAs/mRNAs regulatory pathways at ST using MicroCosm Targets. (DOC)

Table S6 MiRNAs/mRNAs regulatory pathways at IT using MicroCosm Targets. (DOC)

Table S7 MiRNAs/mRNAs regulatory pathways at LT using MicroCosm Targets. (DOC)
Table S8 MiRNAs/mRNAs regulatory pathways in mice model of asthma at ST using TargetScan.

Table S9 MiRNAs/mRNAs regulatory pathways at IT using TargetScan.

Table S10 MiRNAs/mRNAs regulatory pathways at LT using TargetScan.

Acknowledgments

We gratefully thank Professor Betty Nusgens (GIGA-Research, Laboratory of Connective Tissues Biology, University of Liège, Belgium) for her helpful suggestions during the preparation of this manuscript. We also thank Fabienne Perin, Christine Fink, Cédric Lassence and Antoine Heyeres for their technical help.

Author Contributions

Conceived and designed the experiments: NG EDV AC DC. Performed the experiments: NG EDV CC. Analyzed the data: NG EDV VAHT PG AI AC. Contributed reagents/materials/analysis tools: TA CD JP. Wrote the paper: NG AC.

References

1. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G (1998) A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339: 1194–1200.

2. Pascual RM, Peters SP (2005) Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 116: 477–489; quiz 487.

3. Hiro S, Martin JG, Bonacci JV, Chan V, Freeman ED, et al. (2004) Prohlerative aspects of airway smooth muscle. J Allergy Clin Immunol 114: S2–17.

4. Di Valentin E, Crahay C, Garbarick N, Hennuy B, Gueders M, et al. (2009) New asthma biomarkers: lessons from murine models of acute and chronic asthma. Am J Physiol Lung Cell Mol Physiol 296: L185–197.

5. Pennings JL, Kimman TG, Janssen R (2008) Identification of a common gene expression response in different lung inflammatory diseases in rodents and rabbits. PLoS ONE 3: e2596.

6. Noveshtehr N, Inzhalki Z, Manor O, Friedman N, Kaminiski N (2008) A functional and regulatory map of asthma. Am J Respir Cell Mol Biol 36: 324–336.

7. Rolph MS, Stavani M, Liu SM, Mackay CR (2006) Clues to asthma pathogenesis from microarray expression studies. Pharmacol Ther 109: 201–294.

8. Inzhura K, Sato H (2006) Microarray-based identification of novel biomarkers in asthma. Allergol Int 55: 361–367.

9. Park SG, Choi JW, Kim H, Roh GS, Bok J, et al. (2008) Genome-wide profiling of antigen-induced time course expression using murine models for acute and chronic asthma. Int Arch Allergy Immunol 146: 44–56.

10. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, et al. (2003) Alternative splicing in human ESCs: evidence for widespread tissue-specific alternative splicing. J Cell Sci 116: 1863–1874.

11. Muller MA, van Hove CL, Cataldo DD, Gueders MM, Palmans E, et al. (2009) Integrating the MicroRNome into the study of lung disease. Am J Respir Cell Mol Biol 40: 557–560.

12. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD (2008) MicroRNA-mediated antiviral defense in human cells. Science 321: 59–63.

13. Wang Y, Liang Y, Lu Q (2008) MicroRNA antagonism is a common mechanism regulating and pathogenic cell types involved in human disease. Annals of the New York Academy of Sciences 1123: 26–30.

14. Cullen BR (2006) Viruses and microRNAs. Nat Genet 38(Suppl): S25–30.

15. Moosch SA, Williams AE, Perry MM, Birrell MA, Belvisi MG, et al. (2007) Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. BMC Genomics 8: 240.

16. Williams AE, Larner-Svensson H, Perry MM, Campbell GA, Herrick SE, et al. (2009) MicroRNA expression profiling in mild asthmatic human airways and effect of corticosteroid therapy. PLoS ONE 4: e5889.

17. Lu TX, Muniz A, Rothenberg ME (2009) MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol 179: 4–10.

18. Mattes J, Collison A, Plank M, Phipps S, Foster PS (2009) Antagonism of microRNA-122 suppresses the effector function of TH2 cells and the development of allergic airway disease. Proc Natl Acad Sci U S A 106: 18704–18709.

19. Chiba Y, Tanabe M, Goti K, Sakai H, Misawa M (2009) Down-Regulation of miR-133a contributes to Up-Regulation of RhoA in Bronchial Smooth Muscle Cells. Am J Respir Crit Care Med 180: 713–719.

20. Poliak-Papadaki S, Knight JM, Naghavi AO, Opitz T, Creighton CJ, et al. (2010) Proliferative role for let-7 microRNAs in experimental asthma. J Biol Chem 285: 30139–30149.

21. Southam DS, Ellis R, Wattie J, Glass W, Inman MD (2008) Goblet cell rebound and airway dysfunction with corticosteroid withdrawal in a mouse model of asthma. Am J Respir Crit Care Med 178: 1115–1122.

22. Gueders MM, Paulissen G, Crahay C, Quesada-Calvo F, Hacha J, et al. (2009) Mouse models of asthma: a comparison between C57BL/6 and BALB/c strains regarding bronchial responsiveness, inflammation, and cytokine production. Inflamm Res 58: 845–854.

23. Van Hove CL, Maes T, Cataldo DD, Gueders MM, Palms E, et al. (2009) Comparison of acute inflammatory and chronic structural asthma-like responses between C57BL/6 and BALB/c mice. Int Arch Allergy Immunol 149: 195–207.

24. Gueders MM, Bertholet P, Perin F, Rocks N, Marre R, et al. (2008) A novel formulation of inhaled doxycycline reduces allergen-induced inflammation, hyperresponsiveness and remodeling by matrix metalloproteinases and cytokines modulation in a mouse model of asthma. Biochemical Pharmacology 75: 514–526.

25. Tang X, Muniz A, Zhang G, Ozcak S (2009) Identification of glucose-regulated miRNAs from pancreatic (beta) cells reveals a role for miR-90a in insulin transcription. RNA 15: 217–293.

26. Malamuth M, Saroiski KA, Cabedo E, Ruz JW, Jiang X, et al. (2009) Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 113: 3764–3764.

27. Baltimore D, Botten MP, O'Connell RM, Rao DS, Taganov KD (2008) MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9: 839–845.
Wang L, Lepeleyter Y, Hermine O, Nicot C (2009) Deregulation of microRNA-29 family alters Ca2+ entry in atopic dermatitis. J Investig Dermatol 133: 45–51.

Laios A, O'Toole S, Flavin R, Martin C, Kelly I, et al. (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35.

Bhattacharya B, Banerjee S, Laha S, Banerjee S, Das A, et al. (2009) MicroRNA-29b is downregulated in colorectal cancer and predicts patient survival. Int J Cancer 125: 1611–1615.

Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. (2007) MicroRNA-29 family members activate tumor suppressor p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16: 23–29.

Gosens R, Schaafsma D, Grootte Bromhaar MM, Vrugt B, Zaagsma J, et al. (2004) Expression, regulation, and function of C/EBP transcription factors involved in the remodeling and reverse remodeling of the heart. Circulation 110: 813–821.

Buhling F, Rocken M, Gabbow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149–153.

Tzur G, Levy A, Meiri E, Barad O, Spector Y, et al. (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 45–50.

Brazel D, Wilson M, Grozovski T, Schnare M, Rosenfeld MG, et al. (1999) Glucocorticoid receptor interacts with muscle-specific microRNAs (myomirs) in brown adipocytes. J Cell Physiol 180: 327–336.

Bellon M, Lepelletier Y, Hermine O, Nicot C (2009) Deregulation of microRNA in hematopoiesis and the immune response in HTLV-1 infected T-cell leukemia. Blood 113: 4914–4917.

Johnsma JB, Harris MH, Wheeler RT, Stelting Sun S, Lam MH, et al. (2008) Regulation of neurotrophin receptor cell proliferation and granuleocyte function by microRNA-223. Nature 451: 1125–1129.

Anglicheau D, Sharma VK, Ding R, Hummel A, Snopokowski C, et al. (2009) MicroRNA expression profiles predict human of allograft status. Proc Natl Acad Sci U S A 106: 5380–5385.

Laios A, O'Toole S, Flavin R, Martin C, Kelly I, et al. (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35.

Buhling F, Rocken M, Gabbow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149–153.

Wong QW, Lung RW, Law PT, Lai PB, Chan KY, et al. (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates suppression of Sorafenib. Gastroenterology 135: 257–269.

Gottardo F, Liu CG, Ferracin M, Calin GA, Fasan M, et al. (2007) MicroRNA profiling in kidney and bladder cancers. Urol Oncol 25: 317–322.

Wang J, Xu R, Lan F, Zhang S, Zhang G, et al. (2009) MicroRNA: novel regulators involved in the remodeling and reverse remodeling of the heart. Cardiology 113: 81–86.

Walden TB, Timmons JA, Keller P, Nedergaard J, Cannon B (2009) Distinct expression of muscle-specific microRNAs (myomirs) in brown adipocytes. J Cell Physiol 218: 444–449.

Pekarsky Y, Sanmullan U, Cimmino A, Palamarchuk A, Efanov A, et al. (2006) Unique microRNA and molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.

Tzur G, Levy A, Meiri E, Barad O, Spector Y, et al. (2008) Widespread microRNA repression by Mucy contributes to tumorigenesis. Nat Genet 40: 45–50.

Sheedy FJ, O'Neill LA (2008) Adding fuel to fire: microRNAs as a new class of mediators of common clinical responses to therapy. Pharmacol Ther 120: 1–19.

Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 120: 215–224.

Vogel F, Ortiz S, Strahovnik D, Siwiak SR, Ayuso de Dios A, et al. (2009) MicroRNA-mediated repression of the NMDA Receptor subtype NR1 is required for the maintenance of memory. Nat Neurosci 12: 1559–1561.

Clerici M, Polit L, Canale-DiNardo F (2006) Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 533: 133–144.

Mestdagh P, Van Vlerberghe P, De Weer A, Muth D, Westermann F, et al. (2009) A novel and unbiased approach for microRNA RqPCR data normalization. Genome Biol 10: R64.

Meng X, Zhang Y, Wang Q, Zeng L, He F, et al. (2009) miR-30b regulates transforming growth factor beta signaling in human prostate cancer cells. J Cell Physiol 219: 12–20.

Li C, Mao Y, Deng J, Zhang H, Chen Y, et al. (2009) MiR-29a as a novel potential therapeutic target for inhibiting IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J Leukoc Biol 85: 1453–1463.

Huang WJ, Yang W, Cao L, Zhang Y, Chu Q, et al. (2009) miR-29b inhibits the proliferation of human chondrocytes. J Mol Med 87: 631–642.

Legrand A, El-Azhary A, El-Ghaouth A, El-Faramawy E, Mahgoub A, et al. (2009) MiR-29 regulates mammalian cell migration. J Biol Chem 284: 13381–13389.

Shin SM, Kim YH, Choi BK, Kwon PM, Lee HW, et al. (2009) MiR-19a regulates the IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J Leukoc Biol 85: 1453–1463.
104. Li Z, Hassan MQ, Jafferji M, Aqilalri R, Garzon R, et al. (2009) Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 284: 15676–15684.

105. Kuhn C, 3rd, Boldt J, King TE, Jr., Crouch E, Vario T, et al. (1989) An immunohistochimical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 140: 1703-1703.

106. Muro AF, Moretti FA, Moore BB, Yan M, Aratrak RG, et al. (2008) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177: 639–645.

107. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, et al. (2009) MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 11: 1031–1038.

108. Zhang X, Liu S, Hu T, Liu S, He Y, et al. (2009) Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 50: 490–499.

109. Wang Q, Wang Y, Minto AW, Wang J, Shi Q, et al. (2008) MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. Faseb J 22: 4126–4133.

110. Saotome A, Kanai N, Nagai T, Yashiro T, Tokudome S (2003) Immunohistochemical classification of the localization of laminin in the thickened bronchial epithelial basement membrane of deceased bronchial asthma patients. Respir Med 97: 688–694.

111. Meeker TC, Hardy D, Willman C, Hogan T, Abrams J (1990) Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. Blood 76: 285–289.

112. Asquin KL, Ramshef HS, Hansbro PM, Beagley KW, Lopez AF, et al. (2008) The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of TH2 immunity and allergic airway inflammation. J Immunol 180: 1199–1206.

113. Fabry B, Fredberg JJ (2007) Mechanotransduction, asthma, and airway smooth muscle. Drug Discov Today Dis Models 4: 131–137.

114. Turner CE (1998) Molecular in focus Paxillin. The International Journal of Biochemistry & Cell Biology 30: 955–959.

115. Opazo Saez A, Zhang W, Wu Y, Turner CE, Tang DD, et al. (2004) Tension development during contractile stimulation of smooth muscle requires recruitment of paxillin and vinculin to the membrane. Am J Physiol Cell Physiol 286: C143–C147.

116. Ebner S, Hofer S, Nguyen VA, Farhapter C, Herold M, et al. (2002) A novel role for IL-3; human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. J Immunol 168: 6199–6207.

117. Moser M, Murphy KM (2000) Dendritic cell regulation of TH1/TH2 development. Nat Immunol 1: 199–205.

118. Gardino AK, Sledgeron SJ, Yaffe MB (2006) Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol 16: 173–182.

119. Agarwal-Mawal A, Qureshi HY, Cafferty PW, Yuan Z, Han D, et al. (2003) 14-3-3 connects glycoxygen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J Biol Chem 278: 12722–12728.

120. Zhu Q, Hong A, Sheng N, Zhang X, Matejko A, et al. (2007) microParaflo biochip for nucleic acid and protein analysis. Methods Mol Biol 382: 207–312.

121. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185–193.

122. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Bioinformatics 4: 249–264.

123. John B, Enright AJ, Aravin A, Tuschl T, Sander C, et al. (2004) Human MicroRNA targets. PLoS Biol 2: e363.

124. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of microRNA/target duplexes. Rna 10: 1507–1517.

125. Pico AR, Kelder T, van Jersel MP, Hammers K, Conklin BR, et al. (2008) WikiPathways: pathway editing for the people. PLoS Biol 6: e184.

126. Leroy Feklo J, Krishnaiah PR, Sen PK (1986) 6 Combination of independent tests. Handbook of Statistics Elsevier. pp 113–121.